Mutation rate of the CDKN2 gene in malignant gliomas

Cancer Res. 1994 Dec 15;54(24):6338-9.

Abstract

The CDKN2 gene encodes p16, a protein controlling the cell cycle. CDKN2 is deleted in a relevant number of tumor cell lines, but results of the studies in primary tumors are contradictory. We have investigated by using quantitative polymerase chain reaction and single-strand conformation polymorphism analysis the structure of exon 2 of CDKN2 in 32 malignant gliomas. In 11 tumors the amount of amplified material was 21% of that of controls and in 8 tumors it was 42.3%, suggesting the presence of homozygous and hemizygous deletions of the CDKN2 gene, respectively. However, no abnormality could be detected by single-strand conformation polymorphism analysis. The data confirm in primary gliomas that homozygous deletions are a mechanism of CDKN2 inactivation and suggest that another gene in the vicinity could be targeted by mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Carrier Proteins / genetics*
  • Cyclin-Dependent Kinase Inhibitor p16
  • Exons / genetics*
  • Glioma / genetics*
  • Humans
  • Molecular Sequence Data
  • Mutation / genetics*
  • Polymerase Chain Reaction

Substances

  • Carrier Proteins
  • Cyclin-Dependent Kinase Inhibitor p16